Tumor immune microenvironment of EGFR-mutant non-small-cell lung cancer and its impact on therapeutic efficacy

被引：4
|
作者：
Matsumoto, Yoshiya [1 ,2 ]
Koh, Yasuhiro [2 ]
机构：
[1] Osaka City Univ, Grad Sch Med, Dept Resp Med, Osaka, Japan
[2] Wakayama Med Univ, Internal Med 3, Wakayama, Japan
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 07期
关键词：
epidermal growth factor receptor; non-small-cell lung cancer; tumor microenvironment; tumor mutational burden; PD-L1; EXPRESSION; MUTATION INCIDENCE; OPEN-LABEL; PHASE IB; DOCETAXEL; NIVOLUMAB; ATEZOLIZUMAB; BLOCKADE; INFILTRATION; CHEMOTHERAPY;
D O I：
10.2217/imt-2019-0213
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：431 / 438
页数：8
相关论文
共 50 条
  • [21] Impact of concomitant use of anti-acid agents on efficacy of gefitinib in EGFR-mutant non-small-cell lung cancer (NSCLC).
    Chikamori, Kenichi
    Aoe, Keisuke
    Maeda, Tadashi
    Kishino, Daizo
    Oishi, Keiji
    Hotta, Katsuyuki
    Matsumoto, Tsuneo
    Ueoka, Hiroshi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients
    Remon, Jordi
    Planchard, David
    FUTURE ONCOLOGY, 2015, 11 (22) : 3069 - 3081
  • [23] Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Non-Small-Cell Lung Cancer?
    Kulkarni, Amit A.
    Naqash, Abdul Rafeh
    Puri, Sonam
    Dienstmann, Rodrigo
    JCO PRECISION ONCOLOGY, 2021, 5 : 408 - 414
  • [24] Erlotinib response EGFR-mutant gefitinib-resistant non-small-cell lung cancer
    Chang, John Wen-Cheng
    Chou, Chun-Liang
    Huang, Shiu-Feng
    Wang, Hung-Ming
    Hsieh, Jia-Juan
    Hsu, Todd
    Cheung, Yun-Chung
    LUNG CANCER, 2007, 58 (03) : 414 - 417
  • [25] Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors
    Eiki Ichihara
    Daijiro Harada
    Koji Inoue
    Takuo Shibayama
    Shinobu Hosokawa
    Daizo Kishino
    Shingo Harita
    Nobuaki Ochi
    Naohiro Oda
    Naofumi Hara
    Katsuyuki Hotta
    Yoshinobu Maeda
    Katsuyuki Kiura
    Cancer Immunology, Immunotherapy, 2021, 70 : 101 - 106
  • [26] The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer
    Zhong, Wen-Zhao
    Zhou, Qing
    Wu, Yi-Long
    ONCOTARGET, 2017, 8 (41) : 71358 - 71370
  • [27] Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer
    Matsumoto, Yoshiya
    Sawa, Kenji
    Fukui, Mitsuru
    Oyanagi, Jun
    Izumi, Motohiro
    Ogawa, Koichi
    Suzumura, Tomohiro
    Watanabe, Tetsuya
    Kaneda, Hiroyasu
    Mitsuoka, Shigeki
    Asai, Kazuhisa
    Kimura, Tatsuo
    Yamamoto, Nobuyuki
    Koh, Yasuhiro
    Kawaguchi, Tomoya
    CANCER SCIENCE, 2019, 110 (10) : 3244 - 3254
  • [28] Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
    Gomes, Jessica Ribeiro
    Cruz, Marcelo Rocha S.
    ONCOTARGETS AND THERAPY, 2015, 8 : 1137 - 1142
  • [29] Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer
    Soo, Ross A.
    Kim, Hye Ryun
    Asuncion, Bernadette Reyna
    Fazreen, Zul
    Omar, Mohamed Feroz Mohd
    Herrera, Maria Cynthia
    Lim, Joey Sze Yun
    Sia, Grace
    Soong, Richie
    Cho, Byoung-Chul
    LUNG CANCER, 2017, 105 : 17 - 22
  • [30] The Tumor Microenvironment in Non-Small-Cell Lung Cancer
    Graves, Edward E.
    Maity, Amit
    Le, Quynh-Thu
    SEMINARS IN RADIATION ONCOLOGY, 2010, 20 (03) : 156 - 163
12345